Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL-13027 in Advanced Solid Tumors
NCT03869632Phase 1Unknown
- Sponsor
- Yingli Pharma
- Start
- Mar 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YL-13027 in solid tumor (advanced stage), sponsored by Yingli Pharma. Primary endpoints: Dose limited toxicities at 28 days and Adverse events. Status: unknown.
02
Drugs
YL-13027
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03869632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03869632.